![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 31, 2024 12:59:24 AM
The agreement to potentially provide Inspira Technologies with $32.6 million over a 5-year period, subject to regulatory approvals
This adds up to the company’s net income, which was a loss of around 9 million dollars in 2022.
Under the Agreement, Glo-Med shall be designated as the Company's distributor in Saudi Arabia, United Arab Emirates and Bahrain (the "Territory").
Joe Hayon, Inspira Technologies' Co-Founder and President, stated: "This potential expansion into the Gulf states is pivotal for us as we strive to globally distribute our technology for the betterment of patient care."
Matus Knoblich, CEO of Glo-Med, commented: "This agreement is a significant step for us in broadening our range of innovative products to be offered in the healthcare market through our local network of leading distributors in the Territory."
Glo-Med, known for delivering unique healthcare solutions, collaborates with top medical device and biomedical companies worldwide to meet the growing demand for innovative medical devices and related products in
domestic and international markets.
Along with the largest and most prominent healthcare organizations in New York and Florida as clients, Glo-Med has offices and partner companies in the U.S., Latin America, Europe, the Middle East, and Africa, providing extensive access to the global medical network.
https://finance.yahoo.com/news/inspira-technologies-signs-strategic-agreement-133000477.html
Recent IINN News
- Inspira™ Announces Business Plan Targets • PR Newswire (US) • 06/20/2024 01:25:00 PM
- Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel • PR Newswire (US) • 06/17/2024 12:30:00 PM
- Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S. • PR Newswire (US) • 06/13/2024 12:30:00 PM
- Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector • PR Newswire (US) • 06/05/2024 12:30:00 PM
- Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments • PR Newswire (US) • 05/30/2024 12:30:00 PM
- INSPIRA™ ART100 Receives FDA 510(k) Clearance • PR Newswire (US) • 05/28/2024 01:25:00 PM
- Inspira™ Announces Start of Production of the INSPIRA™ ART100 • PR Newswire (US) • 05/02/2024 01:18:00 PM
- Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100 • PR Newswire (US) • 04/25/2024 12:00:00 PM
- Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures • PR Newswire (US) • 04/16/2024 12:42:00 PM
- Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections • PR Newswire (US) • 04/10/2024 12:24:00 PM
- Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb • PR Newswire (US) • 04/03/2024 12:30:00 PM
- Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Inspira™ Technologies Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/25/2024 01:20:00 PM
- Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets • PR Newswire (US) • 03/18/2024 11:00:00 AM
- Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 09:01:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 09:01:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 02:25:02 PM
- Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days • PR Newswire (US) • 03/04/2024 02:20:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 12:15:04 PM
- Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone • PR Newswire (US) • 02/27/2024 12:02:00 PM
- Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements • PR Newswire (US) • 02/27/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 02:18:17 PM
- Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies • PR Newswire (US) • 02/22/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/14/2024 02:18:42 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM